<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:08:30Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9796776" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9796776</identifier>
        <datestamp>2023-01-04</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="add15989" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Addiction</journal-id>
              <journal-id journal-id-type="iso-abbrev">Addiction</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1360-0443</journal-id>
              <journal-id journal-id-type="publisher-id">ADD</journal-id>
              <journal-title-group>
                <journal-title>Addiction (Abingdon, England)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0965-2140</issn>
              <issn pub-type="epub">1360-0443</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9796776</article-id>
              <article-id pub-id-type="pmcid">PMC9796776</article-id>
              <article-id pub-id-type="pmc-uid">9796776</article-id>
              <article-id pub-id-type="pmid">35792053</article-id>
              <article-id pub-id-type="pmid">35792053</article-id>
              <article-id pub-id-type="doi">10.1111/add.15989</article-id>
              <article-id pub-id-type="publisher-id">ADD15989</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Report</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Reports</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Alcohol use in the year following approach bias modification during inpatient withdrawal: secondary outcomes from a double‐blind, multi‐site randomized controlled trial</article-title>
                <alt-title alt-title-type="right-running-head">Alcohol use in the year following ApBM</alt-title>
                <alt-title alt-title-type="left-running-head">Manning et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="add15989-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Manning</surname>
                    <given-names>Victoria</given-names>
                  </name>
                  <xref rid="add15989-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="add15989-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>victoria.manning@monash.edu</email>
                  </address>
                </contrib>
                <contrib id="add15989-cr-0002" contrib-type="author">
                  <name>
                    <surname>Garfield</surname>
                    <given-names>Joshua B. B.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5076-6499</contrib-id>
                  <xref rid="add15989-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="add15989-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0003" contrib-type="author">
                  <name>
                    <surname>Reynolds</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref rid="add15989-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0004" contrib-type="author">
                  <name>
                    <surname>Staiger</surname>
                    <given-names>Petra K.</given-names>
                  </name>
                  <xref rid="add15989-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="add15989-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0005" contrib-type="author">
                  <name>
                    <surname>Piercy</surname>
                    <given-names>Hugh</given-names>
                  </name>
                  <xref rid="add15989-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="add15989-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0006" contrib-type="author">
                  <name>
                    <surname>Bonomo</surname>
                    <given-names>Yvonne</given-names>
                  </name>
                  <xref rid="add15989-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="add15989-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0007" contrib-type="author">
                  <name>
                    <surname>Lloyd‐Jones</surname>
                    <given-names>Martyn</given-names>
                  </name>
                  <xref rid="add15989-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0008" contrib-type="author">
                  <name>
                    <surname>Jacka</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="add15989-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0009" contrib-type="author">
                  <name>
                    <surname>Wiers</surname>
                    <given-names>Reinout W.</given-names>
                  </name>
                  <xref rid="add15989-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0010" contrib-type="author">
                  <name>
                    <surname>Verdejo‐Garcia</surname>
                    <given-names>Antonio</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8874-9339</contrib-id>
                  <xref rid="add15989-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="add15989-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib id="add15989-cr-0011" contrib-type="author">
                  <name>
                    <surname>Lubman</surname>
                    <given-names>Dan I.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6747-1937</contrib-id>
                  <xref rid="add15989-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="add15989-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="add15989-aff-0001" content-type="private-address">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Monash Addiction Research Centre, Eastern Health Clinical School</named-content>
                <institution>Monash University</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="add15989-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Turning Point</named-content>
                <institution>Eastern Health</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="add15989-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Alfred Health and Faculty of Medicine, Nursing and Health Sciences</named-content>
                <institution>Monash University</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="add15989-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">School of Psychology</named-content>
                <institution>Deakin University</institution>
                <city>Geelong</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="add15989-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Centre for Drug use, Addictive and Antisocial behaviour Research (CEDAAR)</named-content>
                <institution>Deakin University</institution>
                <city>Geelong</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="add15989-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Department of Addiction Medicine</named-content>
                <institution>St Vincent's Hospital Melbourne</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="add15989-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Division of Medicine, Dentistry, and Health Sciences</named-content>
                <institution>University of Melbourne</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="add15989-aff-0008" content-type="private-address">
                <label>
                  <sup>8</sup>
                </label>
                <institution>Monash Health Drug and Alcohol Service, Monash Health</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="add15989-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Addiction Development and Psychopathology (ADAPT) Laboratory, Department of Psychology and Center for Urban Mental Health</named-content>
                <institution>University of Amsterdam</institution>
                <city>Amsterdam</city>
                <country country="NL">the Netherlands</country>
              </aff>
              <aff id="add15989-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <named-content content-type="organisation-division">School of Psychological Sciences and Turner Institute for Brain and Mental Health</named-content>
                <institution>Monash University</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Victoria Manning, Turning Point, 110 Church Street, Richmond, VIC, 3121, Australia.<break/>
Email: <email>victoria.manning@monash.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <volume>117</volume>
              <issue seq="120">11</issue>
              <issue-id pub-id-type="doi">10.1111/add.v117.11</issue-id>
              <fpage>2837</fpage>
              <lpage>2846</lpage>
              <history>
                <date date-type="received">
                  <day>27</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>15</day>
                  <month>6</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 Society for the Study of Addiction-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Addiction</italic> published by John Wiley &amp; Sons Ltd on behalf of Society for the Study of Addiction.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:ADD-117-2837.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="add15989-sec-0001">
                  <title>Background and aims</title>
                  <p>Approach bias modification (ApBM) targeting alcohol approach bias has been previously shown to reduce likelihood of relapse during the first 2 weeks following inpatient withdrawal treatment (IWT). We tested whether ApBM’s effects endure for a longer period by analysing alcohol use outcomes 3, 6 and 12 months post‐discharge.</p>
                </sec>
                <sec id="add15989-sec-0002">
                  <title>Design</title>
                  <p>A double‐blind, sham‐controlled randomized controlled trial.</p>
                </sec>
                <sec id="add15989-sec-0003">
                  <title>Setting</title>
                  <p>Four IWT units in Melbourne, Australia.</p>
                </sec>
                <sec id="add15989-sec-0004">
                  <title>Participants</title>
                  <p>Three hundred alcohol IWT patients (173 men, 126 women, 1 non‐binary; mean age 43.5 years) were recruited between 4 June 2017 and 14 July 2019. Follow‐up data collection was completed on 22 September 2020.</p>
                </sec>
                <sec id="add15989-sec-0005">
                  <title>Intervention and control training</title>
                  <p>Four ApBM sessions were delivered during IWT. ApBM trained participants (<italic toggle="yes">n</italic> = 147) to avoid alcohol and approach non‐alcohol beverage cues. Controls (<italic toggle="yes">n</italic> = 153) responded to the same stimuli, but without approach/avoidance training.</p>
                </sec>
                <sec id="add15989-sec-0006">
                  <title>Measurements</title>
                  <p>Date of first lapse was recorded for non‐abstinent participants to determine time to first lapse. Time‐line follow‐back interviews assessed past‐month alcohol consumption at each follow‐up, with participants reporting no alcohol consumption classified as abstinent. In analyses of past‐month abstinence, non‐abstinence was assumed in participants lost to follow‐up. Number of past‐month drinking days, standard drinks and heavy drinking days (five or more standard drinks for women or non‐binary; six or more standard drinks for men) were calculated for non‐abstinent participants at each follow‐up.</p>
                </sec>
                <sec id="add15989-sec-0007">
                  <title>Findings</title>
                  <p>ApBM significantly delayed time to first lapse [ApBM median: 53 days, 95% confidence interval (CI) = 21–61; controls = 12 days, 95% CI = 9–21, <italic toggle="yes">P</italic> = 0.045]. Past‐month abstinence rates at 3‐, 6‐ and 12‐month follow‐ups were 33/153 (21.6%), 30/153 (19.6%), and 24/153 (15.7%) in controls; and 51/147 (34.7%), 30/147 (20.4%) and 29/147 (19.7%) in the ApBM group, respectively. Past‐month abstinence was significantly more likely in ApBM participants than controls at the 3‐month follow‐up [odds ratio (OR) = 1.93, 95% CI = 1.16–3.23, <italic toggle="yes">P</italic> = 0.012], but not at 6‐ or 12‐month follow‐ups (6‐month OR = 1.05, 95% CI = 0.60–1.95, <italic toggle="yes">P</italic> = 0.862; 12‐month OR = 1.32, 95% CI = 0.73–2.40, <italic toggle="yes">P</italic> = 0.360). No significant group differences were found for indices of alcohol consumption in non‐abstinent participants.</p>
                </sec>
                <sec id="add15989-sec-0008">
                  <title>Conclusions</title>
                  <p>Approach bias modification for alcohol delivered during inpatient withdrawal treatment helps to prevent relapse, increasing rates of abstinence from alcohol for at least 3 months post‐discharge.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="add15989-kwd-0001">Alcohol</kwd>
                <kwd id="add15989-kwd-0002">alcohol use disorder</kwd>
                <kwd id="add15989-kwd-0003">approach bias modification</kwd>
                <kwd id="add15989-kwd-0004">cognitive bias modification</kwd>
                <kwd id="add15989-kwd-0005">detoxification</kwd>
                <kwd id="add15989-kwd-0006">relapse</kwd>
                <kwd id="add15989-kwd-0007">withdrawal treatment</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Health and Medical Research Council
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100000925</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <page-count count="10"/>
                <word-count count="6240"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>November 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.3 mode:remove_FC converted:28.12.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="add15989-cit-9001"><string-name><surname>Manning</surname><given-names>V</given-names></string-name>, <string-name><surname>Garfield</surname><given-names>JBB</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>J</given-names></string-name>, <string-name><surname>Staiger</surname><given-names>PK</given-names></string-name>, <string-name><surname>Piercy</surname><given-names>H</given-names></string-name>, <string-name><surname>Bonomo</surname><given-names>Y</given-names></string-name>, et al. <article-title>Alcohol use in the year following approach bias modification during inpatient withdrawal: secondary outcomes from a double‐blind, multi‐site randomized controlled trial</article-title>. <source>Addiction</source>. <year>2022</year>;<volume>117</volume>(<issue>11</issue>):<fpage>2837</fpage>–<lpage>2846</lpage>. <pub-id pub-id-type="doi">10.1111/add.15989</pub-id>
<pub-id pub-id-type="pmid">35792053</pub-id></mixed-citation>
              </p>
              <fn-group>
                <fn id="add15989-note-1002">
                  <p><bold>Funding information</bold> National Health and Medical Research Council</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="add15989-body-0001">
            <sec id="add15989-sec-0009">
              <title>INTRODUCTION</title>
              <p>Cognitive bias modification targeting approach bias, known as approach bias modification (ApBM), is a computerized training intervention that aims to reduce alcohol approach bias (i.e. a behavioural inclination to approach, rather than avoid, alcohol‐associated stimuli) [<xref rid="add15989-bib-0001" ref-type="bibr">1</xref>]. Multiple RCTs have shown that four to 12 ApBM sessions delivered during residential rehabilitation treatment for alcohol use disorder (AUD) significantly reduces rates of relapse by 8–13%, relative to sham‐training or no‐training control groups, at 12‐month follow‐up [<xref rid="add15989-bib-0002" ref-type="bibr">2</xref>, <xref rid="add15989-bib-0003" ref-type="bibr">3</xref>, <xref rid="add15989-bib-0004" ref-type="bibr">4</xref>, <xref rid="add15989-bib-0005" ref-type="bibr">5</xref>]. In a pilot RCT of ApBM delivered during inpatient withdrawal treatment (IWT), those who received the per‐protocol four sessions of training had a significantly (30%) lower rate of relapse 2 weeks post discharge relative to sham‐training controls [<xref rid="add15989-bib-0006" ref-type="bibr">6</xref>]. These findings were recently replicated in a double‐blind, multi‐site RCT with 300 inpatients, where four sessions of ApBM reduced approach bias to alcohol cues and reduced rates of early relapse (defined as any drinking in the first 2 weeks post‐discharge—primary outcome) by 12% (17% with per‐protocol analysis), relative to sham‐training controls [<xref rid="add15989-bib-0007" ref-type="bibr">7</xref>].</p>
              <p>However, the longer‐term efficacy of ApBM delivered during IWT (i.e. beyond the initial 2 weeks post‐discharge) and its comparability to effects when delivered during residential rehabilitation at 1‐year follow‐up has yet to be established. The previous ApBM trials have only assessed alcohol use outcomes at a single end‐point (12 months post training in the residential rehabilitation‐based studies; 2 weeks post training in studies conducted during IWT). As such, it is unclear if the strength of ApBM’s relapse‐prevention effects change over time, e.g. if some patients may benefit in the initial weeks or months following ApBM but relapse before the 12‐month follow‐up. Another limitation of these prior studies is their assessment of single, binary (abstinence/relapse) alcohol consumption outcomes, overlooking other drinking behaviours that may be altered by ApBM. In recognizing that recovery rarely has a linear trajectory and is characterized by set‐backs and intermittent periods of use (‘slips, lapses or relapses’), the inclusion of outcomes other than abstinence in treatment trials is being increasingly endorsed [<xref rid="add15989-bib-0008" ref-type="bibr">8</xref>]. Indeed, understanding if ApBM affects these other drinking outcomes is important, given that many of those seeking treatment for AUD wish to reduce or control their use rather than stop drinking entirely [<xref rid="add15989-bib-0009" ref-type="bibr">9</xref>].</p>
              <p>To address these knowledge gaps, this report examines longer‐term alcohol use outcomes from our multi‐site RCT examining ApBM during alcohol IWT (the primary 2‐week outcome has been previously reported [<xref rid="add15989-bib-0007" ref-type="bibr">7</xref>] and noted above). These include time to first lapse (using survival analysis for the first time in the ApBM literature); rates of abstinence at later follow‐ups (3, 6 and 12 months post‐discharge); and other alcohol consumption outcomes among non‐abstinent participants, including quantity of drinking (standard drinks), frequency of drinking (drinking days) and number of heavy drinking days.</p>
            </sec>
            <sec sec-type="methods" id="add15989-sec-0010">
              <title>METHOD</title>
              <sec id="add15989-sec-0011">
                <title>Trial design and study setting</title>
                <p>The study used a double‐blind, sham‐controlled, parallel‐group randomized clinical trial design with a 1:1 allocation ratio. Recruitment occurred at four alcohol and other drug IWT units in Melbourne, Australia. Training was delivered adjunctive to treatment as usual, which typically lasted approximately 1 week [mean of 7.3, standard deviation (SD) = 2.6 days among trial participants] and included pharmacological management of withdrawal symptoms, group therapeutic activities and referral to post‐withdrawal psychosocial and/or pharmacological treatment as appropriate.</p>
              </sec>
              <sec id="add15989-sec-0012">
                <title>Participants</title>
                <p>Three hundred alcohol IWT patients were randomized between 4 June 2017 and 14 July 2019 (with follow‐ups completed on 22 September 2020). Inclusion criteria were: aged 18–65 years; meeting DSM‐5 criteria for moderate or severe AUD; and at least 5 days’ alcohol use in the 30 days prior to IWT admission. Exclusion criteria were: a diagnosed history of neurological illness, injury or concussion resulting in loss of consciousness exceeding 30 minutes; intellectual disability; or too mentally or physically impaired to provide informed consent or safely participate. Sample size calculation is detailed in the protocol report [<xref rid="add15989-bib-0010" ref-type="bibr">10</xref>] and recruitment was ended following randomization of 300 participants based on this calculation.</p>
              </sec>
              <sec id="add15989-sec-0013">
                <title>Outcome measures</title>
                <p>At each follow‐up, participants were asked if they had consumed any alcohol since the previous follow‐up (or since discharge if no previous follow‐up had been completed) and, if so, when they first consumed alcohol, to determine time to first lapse. The time‐line follow‐back (TLFB) interview method was used to quantify number of days of alcohol use and estimated standard drinks consumed [<xref rid="add15989-bib-0011" ref-type="bibr">11</xref>] in the 30 days preceding inpatient admission at baseline and the 30 days prior to each of the follow‐up interviews.</p>
              </sec>
              <sec id="add15989-sec-0014">
                <title>Interventions</title>
                <sec id="add15989-sec-0015">
                  <title>ApBM condition</title>
                  <p>The ApBM training task has been described in detail previously [<xref rid="add15989-bib-0007" ref-type="bibr">7</xref>, <xref rid="add15989-bib-0010" ref-type="bibr">10</xref>]. To summarize, participants were instructed to respond to images by pushing or pulling a joystick, based on the orientation of the ‘frame’ displayed around the image (pushing if landscape; pulling if portrait). The image shrank or expanded in response to push or pull joystick motions, respectively, to simulate ‘avoidance’ and ‘approach’. Forty images of alcoholic and 40 images of non‐alcoholic beverages were presented three times each (i.e. 240 total image presentations per session) in a random order; 95% of landscape‐orientated frames contained alcoholic images. The remaining 5% of landscape‐orientated presentations contained non‐alcoholic images. Conversely, 95% of portrait‐orientated images contained non‐alcoholic images, and 5% contained alcohol‐related images. As participants were required to ‘push away’ (avoid) images with landscape‐orientated frames and ‘pull’ (approach) images with portrait‐orientated frames, this meant that participants pushed away 95% of alcoholic images (and approached 95% of non‐alcoholic images), implicitly training an avoidance response to alcohol.</p>
                </sec>
                <sec id="add15989-sec-0016">
                  <title>Sham control condition</title>
                  <p>Sham training was identical to the ApBM training, except that each orientation (portrait or landscape) contained alcohol images in 50% of trials and non‐alcohol images the other 50% of trials. Moreover, instead of instructing participants to respond with approach or avoidance movements, participants were instructed to respond with lateral movements of the joystick, according to picture orientation (left for landscape; right for portrait), causing the image to move to the left or right edge of the computer screen without changing size. The sham condition thereby controlled for participants’ exposure to alcohol (and non‐alcohol) images, and for the demand to attend to image orientation and to manipulate the image with a joystick based on orientation, without including the approach/avoidance component hypothesized to underlie the therapeutic effect of ApBM.</p>
                </sec>
              </sec>
              <sec id="add15989-sec-0017">
                <title>Randomization</title>
                <p>Prior to commencing recruitment, a researcher not involved in recruitment or data collection generated site‐specific randomization sequences using a random number generator, based on permuted blocks of variable size. The allocation sequence for each site was incorporated into the training task programme on that site’s task laptop, such that opening the programme and entering the participant number caused the programme to load the allocated training task. Researchers administering the intervention did not have access to the randomization sequences, so were unaware of the participant’s assignment prior to commencement of the first session of training.</p>
              </sec>
              <sec id="add15989-sec-0018">
                <title>Procedure</title>
                <p>Detailed description of the procedure can be found in the protocol [<xref rid="add15989-bib-0010" ref-type="bibr">10</xref>] and on the Australian New Zealand Clinical Trials Registry (ANZCTR; registration number ACTRN12617001241325; registered 25 August 2017). Intake clinicians at participating sites conducted preliminary screening of patients at the time of admission. Those eligible and interested in trial participation met with a researcher, typically on the third day of IWT. If consent to participate was provided, baseline questionnaires confirming eligibility and assessing demographic and clinical characteristics were completed, followed by the first session of ApBM. Subsequent training sessions occurred over the next 3 days (i.e. 4 consecutive days of training in total, one session per day). A researcher not involved in administering the participant’s training (and therefore blinded to their treatment allocation) conducted 3‐, 6‐ and 12‐month telephone follow‐ups. Three‐, 6‐ and 12‐month follow‐ups were conducted 83–129 (mean = 97.2) days, 179–278 (mean = 190.4) days and 361–488 (mean = 377.5) days post‐discharge, respectively. <italic toggle="yes">T</italic>‐tests showed that time to follow‐up did not differ significantly between groups at any follow‐up (all <italic toggle="yes">P</italic> &gt; 0.227). Following intention‐to‐treat (ITT) principles, follow‐ups were pursued with any participant who commenced training, regardless of whether or not they completed the four‐session training protocol, and regardless of whether they had missed previous follow‐ups, unless they withdrew consent to participate. Participants were given $30 (Australian dollars) supermarket gift cards for completing training and $10 gift cards for each follow‐up they completed. This study was approved by the St Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC; reference number 030/17) and the Monash University HREC (project number 8447).</p>
              </sec>
              <sec id="add15989-sec-0019">
                <title>Statistical analysis</title>
                <p>Analyses were conducted in SAS version 9.4 and SPSS version 27. Distributions of times to first lapse were estimated using the Kaplan–Meier product–limit method and groups were compared using the log‐rank test (PROC LIFETEST in SAS version 9.4). Time to first lapse was coded as 0 days if the participant drank alcohol on the day of discharge, 1 day if they first drank alcohol on the day following discharge, etc. Time to first lapse was censored for participants who were continuously abstinent at the time of their final follow‐up. Participants who completed no follow‐ups were censored on day 0.</p>
                <p>Odds of participants reporting past‐month abstinence (i.e. no alcohol consumption in the past 30 days) at each time point analysed (3‐, 6‐ and 12‐month follow‐ups) were compared between groups using logistic regression. In analyses of past‐month abstinence, participants who were lost to follow‐up for any reason were assumed to have consumed alcohol, in accordance with an assumption that this outcome was missing not at random. Additional analyses of rates of continuous abstinence since discharge (i.e. no alcohol use at any point between completing withdrawal treatment and follow‐up) are reported in <xref rid="add15989-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>.</p>
                <p>Additional drinking outcomes among participants who were not past‐month abstinent were analysed at each of the 3‐, 6‐ and 12‐month follow‐ups. These included number of days on which alcohol was consumed in the past 30 days; total standard drinks consumed in the past 30 days; and number of ‘heavy drinking days’ (defined as consumption of at least five standard drinks in a day for women (or non‐binary) or at least six standard drinks in a day for men—note that in Australia a standard drink is defined as 10 g (i.e. 12.7 ml) of pure ethanol). These variables were compared between groups using <italic toggle="yes">t</italic>‐tests. These analyses only used data from participants who completed the follow‐up being analysed (i.e. data were not imputed for participants lost to follow‐up).</p>
                <p>All participants who commenced at least one session of ApBM were included in the primary ITT analysis. We also conducted secondary ‘per‐protocol’ analyses including only those participants who completed four training sessions, which are reported in <xref rid="add15989-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>. Additional, secondary sensitivity analyses are included in the <xref rid="add15989-supitem-0001" ref-type="supplementary-material">Supporting Information</xref> which adjust for the number of previous withdrawal treatment episodes and whether participants had additional drugs of concern aside from alcohol and tobacco. Survival analysis of time to first lapse, analyses of past‐month abstinence and analyses of past‐month drinking days and standard drinks in non‐abstinent participants were pre‐registered in a statistical analysis plan (SAP) that was attached to the trial registration on ANZCTR on 6 February 2019, prior to completion of recruitment. Additional outcomes analysed herein (past‐month heavy drinking days) or in <xref rid="add15989-supitem-0001" ref-type="supplementary-material">supporting information</xref> (continuous abstinence since discharge at follow‐ups)) were not included in the SAP and should be regarded as exploratory.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="add15989-sec-0020">
              <title>RESULTS</title>
              <sec id="add15989-sec-0021">
                <title>Sample characteristics and follow‐ups</title>
                <p>Numbers of patients screened, recruited, randomized and providing data at each follow‐up are shown in Figure <xref rid="add15989-fig-0001" ref-type="fig">1</xref>. Demographic and clinical characteristics of the sample are shown in Table <xref rid="add15989-tbl-0001" ref-type="table">1</xref>. Participants’ first day of ApBM/sham training was typically 3 days after admission (whole sample: mean = 3.0 days post‐admission, SD = 0.9; controls: mean = 3.0, SD = 0.9; ApBM: mean = 3.0, SD = 0.8).</p>
                <fig position="float" fig-type="FIGURE" id="add15989-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Number of patients screened, recruited, randomized and completing each follow‐up</p>
                  </caption>
                  <graphic xlink:href="ADD-117-2837-g002" position="anchor" id="jats-graphic-1"/>
                </fig>
                <table-wrap position="float" id="add15989-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Participants’ demographic, clinical and treatment characteristics</p>
                  </caption>
                  <table frame="hsides" rules="cols">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Total sample (<italic toggle="no">n</italic> = 300)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Controls (<italic toggle="no">n</italic> = 153)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">ApBM group (<italic toggle="no">n</italic> = 147)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">43.5 (10.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">42.3 (10.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">44.7 (10.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Gender</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Men, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">173 (57.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">97 (63.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">76 (51.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Women, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">126 (42.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">55 (36.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">71 (48.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non‐binary, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (0.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (0.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Born in Australia, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">252 (84.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">122 (79.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">130 (88.4)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Aboriginal or Torres Strait Islander, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18 (6.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (5.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10 (6.8)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age at which alcohol use first became problematic, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.3 (10.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.3 (10.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.2 (10.2)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of DSM‐5 AUD criteria met, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.7 (1.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.6 (1.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.8 (1.4)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">SADQ score, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">32.2 (11.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">32.0 (11.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">32.4 (11.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of days alcohol use in 30 days prior to admission, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27.3 (5.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27.1 (5.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27.5 (4.7)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of standard drinks<xref rid="add15989-note-0002" ref-type="table-fn"><sup>a</sup></xref> consumed in 30 days prior to admission, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">589.5 (344.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">588.4 (343.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">590.6 (347.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of heavy drinking days<xref rid="add15989-note-0003" ref-type="table-fn"><sup>b</sup></xref> in 30 days prior to admission, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.5 (6.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.2 (6.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.8 (5.3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any previous withdrawal treatment episodes, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">201 (67.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">110 (71.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">91 (61.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of previous withdrawal treatment episodes, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.7 (4.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.4 (3.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.0 (4.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Current daily tobacco smoker, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">215 (71.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">111 (72.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">104 (70.7)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Current drugs of concern other than alcohol and tobacco, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64 (21.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26 (23.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28 (19.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Current psychiatric diagnosis, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">227 (75.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">114 (74.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">113 (76.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benzodiazepines administered during IWT, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">293 (97.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">150 (98.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">143 (97.3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Anti‐craving medications<xref rid="add15989-note-0004" ref-type="table-fn"><sup>c</sup></xref> administered during IWT, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">148 (49.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">75 (49.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">73 (49.7)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Days spent in IWT, mean (SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.3 (2.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.3 (2.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.4 (3.1)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="add15989-ntgp-0001">
                    <fn id="add15989-note-0001">
                      <p>ApBM, approach bias modification; AUD, alcohol use disorder; DSM‐5, Diagnostic and Statistical Manual of Mental Disorders; IWT, inpatient withdrawal treatment; SADQ, Severity of Alcohol Dependence Questionnaire; SD, standard deviation.</p>
                    </fn>
                    <fn id="add15989-note-0002">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>In Australia, a standard drink is defined at 10 g of pure ethanol.</p>
                    </fn>
                    <fn id="add15989-note-0003">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Heavy drinking days were defined as six or more standard drinks for men or five or more standard drinks for women and non‐binary participants.</p>
                    </fn>
                    <fn id="add15989-note-0004">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Medication classified as anti‐craving medications included acamprosate, naltrexone, baclofen and disulfiram.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="add15989-sec-0022">
                <title>Survival analysis of time to first lapse</title>
                <p>Estimated percentages of participants maintaining continuous abstinence, as a function of time since discharge, are shown in Figure <xref rid="add15989-fig-0002" ref-type="fig">2</xref>. While approximately one‐third of participants in both groups lapsed within the first week following discharge, the groups then diverged, with the ApBM group maintaining a notably higher continuous abstinence rate than controls for several months afterwards. In Figure <xref rid="add15989-fig-0002" ref-type="fig">2</xref>, this difference between groups is most visually apparent approximately 1–2 months following discharge, with groups’ rates of continuous abstinence appearing to re‐converge approximately 4–5 months post‐discharge. Kaplan–Meier analysis confirmed a significant difference between groups (log‐rank test χ<sup>2</sup> = 4.03, <italic toggle="yes">P</italic> = 0.045). Time taken for 25%, 50% and 75% of the control group to lapse was 3 [95% confidence interval (CI) = 1–4], 12 (95% CI = 9–21) and 76 (95% CI = 50–134) days, respectively, while for the ApBM group, these values were 3 (95% CI = 2–5), 53 (95% CI = 21–61) and 127 (95% CI = 84–176). As such, median time to first lapse was more than four times as long in the ApBM group compared to the control group. The effect of group remained significant in per‐protocol and adjusted sensitivity analyses described in the <xref rid="add15989-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>.</p>
                <fig position="float" fig-type="FIGURE" id="add15989-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Percentage of participants in each group maintaining continuous abstinence since discharge as a function of days since discharge. Shading shows 95% confidence intervals. Vertical bars on the Kaplan–Meier curves indicate abstinent participants censored at their last assessment date. Dotted lines show time taken for 50% of participants in each group to lapse</p>
                  </caption>
                  <graphic xlink:href="ADD-117-2837-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
              </sec>
              <sec id="add15989-sec-0023">
                <title>Past‐month abstinence</title>
                <p>Proportions of participants abstinent from alcohol at each follow‐up are shown in Table <xref rid="add15989-tbl-0002" ref-type="table">2</xref>. The rate of past‐month abstinence was significantly (13.1%) higher in the ApBM group than controls at the 3‐month follow‐up. Between‐group differences were non‐significant at later (6‐ and 12‐month) follow‐ups, although abstinence rates remained slightly higher in the ApBM group, relative to controls, at both time‐points. This general pattern (significant effect of group at 3‐month follow‐up, but not 6‐ or 12‐month follow‐ups) remained in per protocol (OR = 2.17) and adjusted sensitivity analyses (OR = 1.94) (see <xref rid="add15989-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>). Rates of continuous abstinence since discharge at each follow‐up are shown in the <xref rid="add15989-supitem-0001" ref-type="supplementary-material">Supporting Information</xref> and did not reveal significant between‐group differences.</p>
                <table-wrap position="float" id="add15989-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Numbers and percentages of participants abstinent for the past 30 days at each follow‐up</p>
                  </caption>
                  <table frame="hsides" rules="cols">
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Time</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Control (<italic toggle="yes">n</italic> = 153)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">ApBM (<italic toggle="yes">n</italic> = 147)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">OR</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">95% CI of OR</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <italic toggle="no">P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">3‐month, <italic toggle="yes">n</italic> (%, 95% CI)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">33 (21.6, 15.3–28.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">51 (34.7, 27.0–43.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.93</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.16–3.23</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.012<xref rid="add15989-note-1105" ref-type="table-fn">*</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">6‐month, <italic toggle="yes">n</italic> (%, 95% CI)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">30 (19.6, 13.6–26.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">30 (20.4, 14.2–27.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.05</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.60–1.85</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.862</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">12‐month, <italic toggle="yes">n</italic> (%, 95% CI)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">24 (15.7, 10.3–22.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">29 (19.7, 13.6–27.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.32</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.73–2.40</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.360</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="add15989-ntgp-0002">
                    <fn id="add15989-note-0005">
                      <p>ApBM, approach bias modification; CI, confidence interval; OR, odds ratio.</p>
                    </fn>
                    <fn id="add15989-note-1105">
                      <label>*</label>
                      <p><italic toggle="yes">P</italic> &lt; 0.05.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="add15989-sec-0024">
                <title>Alcohol use in participants who were not abstinent at each follow‐up</title>
                <p>Mean number of drinking days, standard drinks and heavy drinking days among participants who were not abstinent for the past month at each follow‐up are shown in Table <xref rid="add15989-tbl-0003" ref-type="table">3</xref>. While values of these variables were substantially lower than at baseline, there were no significant differences between groups at any follow‐up. Per‐protocol and adjusted sensitivity analyses also did not reveal significant effects of group for these outcomes (see <xref rid="add15989-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>).</p>
                <table-wrap position="float" id="add15989-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Alcohol use outcomes among participants who were not abstinent at each follow‐up</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Time</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Drinking outcome</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Control, mean (SD)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">ApBM, mean (SD)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <italic toggle="no">t</italic>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <italic toggle="no">P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td rowspan="3" align="left" valign="top" colspan="1">3‐month</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Drinking days</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">16.9 (11.0)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">17.1 (10.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.09</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.929</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Standard drinks</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">220.3 (195.8)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">229.6 (245.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.805</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Heavy drinking days</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">13.9 (11.0)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">14.4 (11.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.24</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.809</td>
                      </tr>
                      <tr>
                        <td rowspan="3" align="left" valign="top" colspan="1">6‐month</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Drinking days</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">17.1 (11.1)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">17.8 (11.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.689</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Standard drinks</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">221.8 (215.9)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">243.1 (253.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.57</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.571</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Heavy drinking days</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">13.8 (11.8)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">15.9 (12.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−1.04</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.299</td>
                      </tr>
                      <tr>
                        <td rowspan="3" align="left" valign="top" colspan="1">12‐month</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Drinking days</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">18.3 (10.3)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">19.2 (11.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.51</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.611</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Standard drinks</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">216.6 (195.3)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">247.0 (230.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.89</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.376</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Heavy drinking days</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">14.5 (11.4)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">15.8 (12.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.65</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.518</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="add15989-ntgp-0003">
                    <fn id="add15989-note-0006">
                      <p>ApBM, approach bias modification; SD, standard deviation.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="add15989-sec-0025">
                <title>Differences between participants completing follow‐ups and those lost to follow‐up</title>
                <p>To test potential sources of bias in outcome measurement, we compared participants who completed follow‐ups and those who did not in terms of baseline demographic and clinical variables, as well as allocated group, at each follow‐up. Variables tested included age, gender, age at which alcohol use became problematic, any previous withdrawal treatment episodes, current daily tobacco use, presence of additional drugs of concern other than alcohol or tobacco, number of days alcohol use in the 30 days prior to IWT admission, number of standard drinks consumed in the 30 days prior to IWT admission and allocated group. The only significant differences detected were that completers were significantly older at the 3‐month (completers mean = 44.3, SD = 10.1 years; non‐completers mean = 40.7, SD = 11.0 years; <italic toggle="yes">t</italic>
<sub>(298)</sub> = −2.56, <italic toggle="yes">P</italic> = 0.011), 6‐month (completers mean = 44.3, SD = 10.1 years; non‐completers mean = 41.1, SD = 11.2 years; <italic toggle="yes">t</italic>
<sub>(298)</sub> = −2.34, <italic toggle="yes">P</italic> = 0.020) and 12‐month follow‐ups (completers mean = 44.5, SD = 10.1 years; non‐completers mean = 41.2, SD = 10.9 years; <italic toggle="yes">t</italic>
<sub>(298)</sub> = −2.53, <italic toggle="yes">P</italic> = 0.012).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="add15989-sec-0026">
              <title>DISCUSSION</title>
              <p>The findings of this double‐blind RCT demonstrate for the first time that four sessions of ApBM significantly delays the time to first drink among ApBM participants during the initial months post‐discharge, extending median time to first lapse until day 53 (relative to day 12 in controls). Although visual examination of survival curves suggested some convergence in continuous abstinence rates after several months, past‐month abstinence rates were still 13% higher among participants who received ApBM than among sham‐trained controls 3 months after discharge from IWT. The finding that the effects of ApBM were detectable at least 3 months post‐discharge is particularly encouraging in light of the brevity (totalling just 1 hour of training during detoxification), low cost and simplicity of the intervention. As ApBM was shown to significantly reduce alcohol approach bias in our earlier report on this trial’s primary outcome [<xref rid="add15989-bib-0007" ref-type="bibr">7</xref>] it is possible that automatic responses to alcohol cues, which are ubiquitous in the community in countries such as Australia, remain diminished for at least several months. Reducing vulnerability to cue‐induced relapse during this post‐discharge period may also facilitate participants’ uptake and engagement in psychosocial and pharmacological treatments that can improve long‐term outcomes [<xref rid="add15989-bib-0012" ref-type="bibr">12</xref>, <xref rid="add15989-bib-0013" ref-type="bibr">13</xref>, <xref rid="add15989-bib-0014" ref-type="bibr">14</xref>].</p>
              <p>However, in contrast to studies where ApBM was administered during longer‐term residential rehabilitation treatment after withdrawal was completed [<xref rid="add15989-bib-0002" ref-type="bibr">2</xref>, <xref rid="add15989-bib-0003" ref-type="bibr">3</xref>, <xref rid="add15989-bib-0004" ref-type="bibr">4</xref>, <xref rid="add15989-bib-0005" ref-type="bibr">5</xref>], which found significant effects on abstinence rates a year after discharge, we found no significant differences between groups in rates of abstinence at 6‐ and 12‐month follow‐ups. This suggests that the durability of ApBM’s effects may be lower when delivered in a more acute treatment setting and/or with a shorter and more compressed training schedule. Alternatively, the differences between our findings and those of studies based in rehabilitation settings may reflect differences in patient populations. With regard to other drinking outcomes (quantity and frequency of use) in non‐abstinent participants, no significant group differences were found. This suggests that while ApBM had efficacy in preventing or delaying the first drink following withdrawal treatment, once drinking had recommenced it had little or no effect on the quantity or frequency of consumption. One potential explanation for this is that drinking may reinstate approach bias that was present prior to ApBM, overriding expression of the avoidance bias learned during ApBM. This would be analogous to the drug‐induced reinstatement of drug‐seeking that has been reported following extinction of conditioned responding for drugs demonstrated in animal models of addiction [<xref rid="add15989-bib-0015" ref-type="bibr">15</xref>, <xref rid="add15989-bib-0016" ref-type="bibr">16</xref>, <xref rid="add15989-bib-0017" ref-type="bibr">17</xref>]. Indeed, in an experimental study examining approach bias to smoking cues in tobacco smokers before and after smoking a cigarette, smoking caused an immediate increase in tobacco approach bias, relative to participants who were denied the opportunity to smoke between the two approach bias assessments, despite craving being reduced following smoking [<xref rid="add15989-bib-0018" ref-type="bibr">18</xref>]. The reinstatement of alcohol approach bias following resumption of alcohol use may be further facilitated by contextual cues such as the social and physical environments where alcohol is obtained and consumed.</p>
              <p>It is possible that the short‐term relapse prevention effects of ApBM during IWT could be extended with further/booster ApBM sessions post‐discharge. While repeated visits to treatment services to undertake training sessions may be impractical, there are remotely accessible ApBM formats, including online training, where drinking has been found to reduce following ApBM (although not to a greater extent than among sham‐trained controls) [<xref rid="add15989-bib-0019" ref-type="bibr">19</xref>]. Alternatively, smartphone‐delivered ApBM has recently been explored in two uncontrolled single arm studies, with both demonstrating positive (and similar) findings in terms of significant reductions in drinking [<xref rid="add15989-bib-0020" ref-type="bibr">20</xref>, <xref rid="add15989-bib-0021" ref-type="bibr">21</xref>]. Importantly, smartphone ApBM could allow patients to engage in post‐discharge ApBM in multiple, naturalistic contexts, including those where alcohol could be consumed, which could reduce the potential for reinstatement/renewal effects.</p>
              <p>Limitations of the study included all outcomes being assessed using self‐report, although the TLFB interview method is considered a valid measure of recent substance use under conditions in which it was administered (i.e. by a researcher independent of the treatment team and with confidentiality ensured) [<xref rid="add15989-bib-0022" ref-type="bibr">22</xref>, <xref rid="add15989-bib-0023" ref-type="bibr">23</xref>]. Another limitation is attrition, which reached 31% of participants by the 12‐month follow‐up, although this rate is typical of outcomes studies of this population [<xref rid="add15989-bib-0002" ref-type="bibr">2</xref>, <xref rid="add15989-bib-0024" ref-type="bibr">24</xref>]. This could reduce precision of the findings as well as potentially biasing them, particularly since younger participants had a higher rate of attrition than older participants. However, at no time‐point did rates of attrition differ significantly between groups, nor were there any other significant demographic or clinical characteristic differences, aside from age, between follow‐up completers and those lost to follow‐up. Finally, while we sought to maintain blinding by using a control condition which included the same stimuli and very similar task demands, we did not formally assess participants’ blinding at follow‐up. Although participants gave very similar post‐intervention ratings of the two conditions in terms of how interesting the training was and how much they felt it affected their craving and attention (see Supporting Information in Manning <italic toggle="yes">et al</italic>. [<xref rid="add15989-bib-0007" ref-type="bibr">7</xref>]), suggesting minimal subjective difference between the tasks, we did not explicitly ask them to which condition they believed they had been randomized. We therefore cannot rule out the possibility that placebo/expectancy effects resulting from blinding failure influenced our findings.</p>
              <p>Despite these limitations, the trial has multiple strengths that have been absent in previous ApBM trials, including multiple outcomes assessed at multiple time‐points. These findings provide increased clarity on the durability of ApBM relapse prevention effects following IWT, and suggest it tends to be strongest during the first few months following discharge and wanes over time. These outcomes add to our confidence that ApBM is a valuable relapse prevention tool when added to residential treatment, including inpatient withdrawal. Future research should examine the value of post‐discharge booster sessions of ApBM as part of outpatient management following IWT to extend the durability of ApBM’s effect.</p>
            </sec>
            <sec id="add15989-sec-0028">
              <title>CLINICAL TRIAL REGISTRATION</title>
              <p>This trial was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR; trial registration number ACTRN12617001241325) on 25 August 2017. Registration was completed 82 days after commencing recruitment (4 June 2017) and we had recruited 58 participants (19% of the eventual total sample of 300) by this time. No 3‐, 6‐ or 12‐month follow‐ups had been completed, and we had not examined any data collected or conducted any interim/preliminary analyses at the time of registration.</p>
            </sec>
            <sec id="add15989-sec-0027">
              <title>DECLARATION OF INTERESTS</title>
              <p>V.M. and H.P. are founders, directors and shareholders of Cognitive Training Solutions Pty Ltd, which recently began commercializing the ‘SWiPE’ smartphone application, which offers approach bias modification. D.I.L. has provided consultancy advice to Lundbeck and Indivior outside the submitted work; has received travel support and speaker honoraria from AstraZeneca, Camurus, Indivior, Janssen, Lundbeck, Shire and Servier outside the submitted work; and has been an investigator on an untied education grant from Sequirus unrelated to the current work. J.R. has received grants from AbbVie outside the submitted work, being a former employee of Novartis AG (2009–2012), and holding shares in Novartis AG and ALCON. A.V.‐G. has received personal fees from Servier and Elsevier outside the submitted work, and is part of the Scientific Advisory Board of Monclarity/Brainwell, which produces cognitive training games (but does not receive any honorarium for this role). M.L.‐J. has received speaking honoraria from Indivior outside the submitted work. Y.B. has provided consultancy advice to Indivior and AbbVie outside the submitted work. She has been an investigator on a clinical trial for Zelira Therapeutics unrelated to the current work. No other authors have any conflicts of interest to declare.</p>
            </sec>
            <sec id="add15989-sec-0030">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Victoria Manning:</bold> Conceptualization; funding acquisition; investigation; methodology; project administration; supervision. <bold>Joshua Garfield:</bold> Conceptualization; data curation; formal analysis; investigation; methodology; project administration; supervision. <bold>John Reynolds:</bold> Conceptualization; data curation; formal analysis; funding acquisition; methodology; software. <bold>Petra Staiger:</bold> Conceptualization; funding acquisition; methodology. <bold>Hugh Piercy:</bold> Data curation; project administration. <bold>Yvonne Bonomo:</bold> Project administration; resources. <bold>Martyn Lloyd‐Jones:</bold> Project administration; resources. <bold>David Jacka:</bold> Project administration; resources. <bold>Reinout Wiers:</bold> Conceptualization; methodology. <bold>Antonio Verdejo‐García:</bold> Conceptualization; funding acquisition; methodology. <bold>Dan Lubman:</bold> Conceptualization; funding acquisition; resources.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="add15989-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>Table S1.</bold> Percentages of participants continuously abstinent since discharge at each follow‐up</p>
                  <p><bold>Table S2.</bold> Past‐month and continuous abstinence rates in the per‐protocol analysis set</p>
                  <p><bold>Table S3.</bold> Alcohol use outcomes among participants who were not abstinent at each follow‐up in the per‐protocol analysis set.</p>
                  <p><bold>Table S4.</bold> Odds ratios for effect of group on rates of abstinence after adjustment for number of previous inpatient withdrawal treatment episodes and presence of any additional drugs of concern</p>
                  <p><bold>Table S5.</bold> Analyses of effects of group on alcohol consumption among non‐abstinent participants, adjusted for number of previous withdrawal treatment episodes and presence of additional drugs of concern.</p>
                </caption>
                <media xlink:href="ADD-117-2837-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="add15989-sec-0029">
              <title>ACKNOWLEDGEMENTS</title>
              <p>This project was funded by a National Health and Medical Research Council (NHMRC) project grant 1124604. We acknowledge Associate Professor Jarrad A. G. Lum’s contribution to programming the approach bias modification and sham control training tasks. We thank the directors and staff of the recruitment sites for facilitating our access to their clients, and would particularly like to acknowledge Angela Fazio, Jennifer Kelly, Oonagh McNamara, Molly O’Reilly, Michelle Cody, Kelvin Hicks, Alex Lebani, Trudy Trice and Bernadette De Boer for their role in this. We also acknowledge the role of Katherine Mroz, Samuel C. Campbell, Kristina Vujcic, Ingrid Zhang, Thomas Tolliday, Patrick Haylock, Alexandra Turnbull, Emily Darmanin and Nyssa Ferguson in recruiting participants, conducting training sessions and collecting, entering and cleaning data. We thank Danielle Whelan for her help preparing the figures in the paper. We also thank Dr Kate Hall for her role in assisting with the design of the study and obtaining funding. Open access publishing facilitated by Monash University, as part of the Wiley ‐ Monash University agreement via the Council of Australian University Librarians.</p>
            </ack>
            <ref-list id="add15989-bibl-0001" content-type="cited-references">
              <title>REFERENCES</title>
              <ref id="add15989-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0002"><string-name><surname>Wiers</surname><given-names>RW</given-names></string-name>, <string-name><surname>Rinck</surname><given-names>M</given-names></string-name>, <string-name><surname>Kordts</surname><given-names>R</given-names></string-name>, <string-name><surname>Houben</surname><given-names>K</given-names></string-name>, <string-name><surname>Strack</surname><given-names>F</given-names></string-name>. <article-title>Retraining automatic action‐tendencies to approach alcohol in hazardous drinkers</article-title>. <source>Addiction</source>. <year>2010</year>;<volume>105</volume>:<fpage>279</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">20078486</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0003"><string-name><surname>Eberl</surname><given-names>C</given-names></string-name>, <string-name><surname>Wiers</surname><given-names>RW</given-names></string-name>, <string-name><surname>Pawelczack</surname><given-names>S</given-names></string-name>, <string-name><surname>Rinck</surname><given-names>M</given-names></string-name>, <string-name><surname>Becker</surname><given-names>ES</given-names></string-name>, <string-name><surname>Lindenmeyer</surname><given-names>J</given-names></string-name>. <article-title>Approach bias modification in alcohol dependence: do clinical effects replicate and for whom does it work best?</article-title><source>Dev Cogn Neurosci</source>. <year>2013</year>;<volume>4</volume>:<fpage>38</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">23218805</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0004"><string-name><surname>Rinck</surname><given-names>M</given-names></string-name>, <string-name><surname>Wiers</surname><given-names>RW</given-names></string-name>, <string-name><surname>Becker</surname><given-names>ES</given-names></string-name>, <string-name><surname>Lindenmeyer</surname><given-names>J</given-names></string-name>. <article-title>Relapse prevention in abstinent alcoholics by cognitive bias modification: clinical effects of combining approach bias modification and attention bias modification</article-title>. <source>J Consult Clin Psychol</source>. <year>2018</year>;<volume>86</volume>:<fpage>1005</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">30507226</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0005"><string-name><surname>Salemink</surname><given-names>E</given-names></string-name>, <string-name><surname>Rinck</surname><given-names>M</given-names></string-name>, <string-name><surname>Becker</surname><given-names>E</given-names></string-name>, <string-name><surname>Wiers</surname><given-names>RW</given-names></string-name>, <string-name><surname>Lindenmeyer</surname><given-names>J</given-names></string-name>. <article-title>Does comorbid anxiety or depression moderate effects of approach bias modification in the treatment of alcohol use disorders?</article-title><source>Psychol Addict Behav</source>. <year>2021</year>. <pub-id pub-id-type="doi">10.1037/adb0000642</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0006"><string-name><surname>Wiers</surname><given-names>RW</given-names></string-name>, <string-name><surname>Eberl</surname><given-names>C</given-names></string-name>, <string-name><surname>Rinck</surname><given-names>M</given-names></string-name>, <string-name><surname>Becker</surname><given-names>ES</given-names></string-name>, <string-name><surname>Lindenmeyer</surname><given-names>J</given-names></string-name>. <article-title>Retraining automatic action tendencies changes alcoholic patients’ approach bias for alcohol and improves treatment outcome</article-title>. <source>Psychol Sci</source>. <year>2011</year>;<volume>22</volume>:<fpage>490</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">21389338</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0007"><string-name><surname>Manning</surname><given-names>V</given-names></string-name>, <string-name><surname>Staiger</surname><given-names>PK</given-names></string-name>, <string-name><surname>Hall</surname><given-names>K</given-names></string-name>, <string-name><surname>Garfield</surname><given-names>JBB</given-names></string-name>, <string-name><surname>Flaks</surname><given-names>G</given-names></string-name>, <string-name><surname>Leung</surname><given-names>D</given-names></string-name>, et al. <article-title>Cognitive bias modification training during inpatient alcohol detoxification reduces early relapse: a randomized controlled trial</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2016</year>;<volume>40</volume>:<fpage>2011</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">27488392</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0008"><string-name><surname>Manning</surname><given-names>V</given-names></string-name>, <string-name><surname>Garfield</surname><given-names>JBB</given-names></string-name>, <string-name><surname>Staiger</surname><given-names>PK</given-names></string-name>, <string-name><surname>Lubman</surname><given-names>DI</given-names></string-name>, <string-name><surname>Lum</surname><given-names>JAG</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>J</given-names></string-name>, et al. <article-title>Effect of cognitive bias modification on early relapse among adults undergoing inpatient alcohol withdrawal treatment: a randomized clinical trial</article-title>. <source>JAMA Psychiatry</source>. <year>2021</year>;<volume>78</volume>:<fpage>133</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">33146693</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0009"><string-name><surname>Paquette</surname><given-names>CE</given-names></string-name>, <string-name><surname>Daughters</surname><given-names>SB</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>. <article-title>Expanding the continuum of substance use disorder treatment: nonabstinence approaches</article-title>. <source>Clin Psychol Rev</source>. <year>2022</year>;<volume>91</volume>:<elocation-id>102110</elocation-id>.<pub-id pub-id-type="pmid">34864497</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0010"><string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>ML</given-names></string-name>, <string-name><surname>Fertig</surname><given-names>JB</given-names></string-name>, <string-name><surname>Devine</surname><given-names>EG</given-names></string-name>, <string-name><surname>Cruz</surname><given-names>R</given-names></string-name>, <string-name><surname>Brown</surname><given-names>ES</given-names></string-name>, et al. <article-title>Gabapentin Enacarbil extended‐release for alcohol use disorder: a randomized, double‐blind, placebo‐controlled, multisite trial assessing efficacy and safety</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2019</year>;<volume>43</volume>:<fpage>158</fpage>–<lpage>69</lpage>.<pub-id pub-id-type="pmid">30403402</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0011"><string-name><surname>Manning</surname><given-names>V</given-names></string-name>, <string-name><surname>Garfield</surname><given-names>JBB</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>SC</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>J</given-names></string-name>, <string-name><surname>Staiger</surname><given-names>PK</given-names></string-name>, <string-name><surname>Lum</surname><given-names>JAG</given-names></string-name>, et al. <article-title>Protocol for a randomised controlled trial of cognitive bias modification training during inpatient withdrawal from alcohol use disorder</article-title>. <source>Trials</source>. <year>2018</year>;<volume>19</volume>:<fpage>598</fpage>.<pub-id pub-id-type="pmid">30382877</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="book" id="add15989-cit-0012"><string-name><surname>Sobell</surname><given-names>LC</given-names></string-name>, <string-name><surname>Sobell</surname><given-names>MB</given-names></string-name>. <source>Timeline Followback User’s Guide: A Calendar Method for Assessing Alcohol and Drug Use</source><publisher-loc>Toronto, Canada</publisher-loc>: <publisher-name>Addiction Research Foundation</publisher-name>; <year>1996</year>.</mixed-citation>
              </ref>
              <ref id="add15989-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0013"><string-name><surname>Jonas</surname><given-names>DE</given-names></string-name>, <string-name><surname>Amick</surname><given-names>HR</given-names></string-name>, <string-name><surname>Feltner</surname><given-names>C</given-names></string-name>, <string-name><surname>Bobashev</surname><given-names>G</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>K</given-names></string-name>, <string-name><surname>Wines</surname><given-names>R</given-names></string-name>, et al. <article-title>Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta‐analysis</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>311</volume>:<fpage>1889</fpage>–<lpage>900</lpage>.<pub-id pub-id-type="pmid">24825644</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0014"><string-name><surname>Magill</surname><given-names>M</given-names></string-name>, <string-name><surname>Ray</surname><given-names>L</given-names></string-name>, <string-name><surname>Kiluk</surname><given-names>B</given-names></string-name>, <string-name><surname>Hoadley</surname><given-names>A</given-names></string-name>, <string-name><surname>Bernstein</surname><given-names>M</given-names></string-name>, <string-name><surname>Tonigan</surname><given-names>JS</given-names></string-name>, et al. <article-title>A meta‐analysis of cognitive–behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition</article-title>. <source>J Consult Clin Psychol</source>. <year>2019</year>;<volume>87</volume>:<fpage>1093</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">31599606</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0015"><string-name><surname>Smedslund</surname><given-names>G</given-names></string-name>, <string-name><surname>Berg</surname><given-names>RC</given-names></string-name>, <string-name><surname>Hammerstrøm</surname><given-names>KT</given-names></string-name>, <string-name><surname>Steiro</surname><given-names>A</given-names></string-name>, <string-name><surname>Leiknes</surname><given-names>KA</given-names></string-name>, <string-name><surname>Dahl</surname><given-names>HM</given-names></string-name>, et al. <article-title>Motivational interviewing for substance abuse</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2011</year>;<volume>5</volume>:<fpage>1</fpage>–<lpage>126</lpage>.</mixed-citation>
              </ref>
              <ref id="add15989-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0016"><string-name><surname>Bouton</surname><given-names>ME</given-names></string-name>. <article-title>Context, ambiguity, and unlearning: sources of relapse after behavioral extinction</article-title>. <source>Biol Psychiatry</source>. <year>2002</year>;<volume>52</volume>:<fpage>976</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="pmid">12437938</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0017"><string-name><surname>Bouton</surname><given-names>ME</given-names></string-name>, <string-name><surname>Swartzentruber</surname><given-names>D</given-names></string-name>. <article-title>Sources of relapse after extinction in Pavlovian and instrumental learning</article-title>. <source>Clin Psychol Rev</source>. <year>1991</year>;<volume>11</volume>:<fpage>123</fpage>–<lpage>40</lpage>.</mixed-citation>
              </ref>
              <ref id="add15989-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0018"><string-name><surname>Shaham</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shalev</surname><given-names>U</given-names></string-name>, <string-name><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name><surname>de Wit</surname><given-names>H</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>J</given-names></string-name>. <article-title>The reinstatement model of drug relapse: history, methodology and major findings</article-title>. <source>Psychopharmacology</source>. <year>2003</year>;<volume>168</volume>:<fpage>3</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">12402102</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0019"><string-name><surname>Watson</surname><given-names>P</given-names></string-name>, <string-name><surname>de Wit</surname><given-names>S</given-names></string-name>, <string-name><surname>Cousijn</surname><given-names>J</given-names></string-name>, <string-name><surname>Hommel</surname><given-names>B</given-names></string-name>, <string-name><surname>Wiers</surname><given-names>RW</given-names></string-name>. <article-title>Motivational mechanisms underlying the approach bias to cigarettes</article-title>. <source>J Exp Psychopathol</source>. <year>2013</year>;<volume>4</volume>:<fpage>250</fpage>–<lpage>62</lpage>.</mixed-citation>
              </ref>
              <ref id="add15989-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0020"><string-name><surname>Wiers</surname><given-names>RW</given-names></string-name>, <string-name><surname>Houben</surname><given-names>K</given-names></string-name>, <string-name><surname>Fadardi</surname><given-names>JS</given-names></string-name>, <string-name><surname>van Beek</surname><given-names>P</given-names></string-name>, <string-name><surname>Rhemtulla</surname><given-names>M</given-names></string-name>, <string-name><surname>Cox</surname><given-names>WM</given-names></string-name>. <article-title>Alcohol cognitive bias modification training for problem drinkers over the web</article-title>. <source>Addict Behav</source>. <year>2015</year>;<volume>40</volume>:<fpage>21</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">25218067</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0021"><string-name><surname>Laurens</surname><given-names>MC</given-names></string-name>, <string-name><surname>Pieterse</surname><given-names>ME</given-names></string-name>, <string-name><surname>Brusse‐Keizer</surname><given-names>M</given-names></string-name>, <string-name><surname>Salemink</surname><given-names>E</given-names></string-name>, <string-name><surname>Ben Allouch</surname><given-names>S</given-names></string-name>, <string-name><surname>Bohlmeijer</surname><given-names>ET</given-names></string-name>, et al. <article-title>Alcohol avoidance training as a Mobile app for problem drinkers: longitudinal feasibility study</article-title>. <source>J Med Internet Res Mhealth Uhealth</source>. <year>2020</year>;<volume>8</volume>:<elocation-id>e16217</elocation-id>.</mixed-citation>
              </ref>
              <ref id="add15989-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0022"><string-name><surname>Manning</surname><given-names>V</given-names></string-name>, <string-name><surname>Piercy</surname><given-names>H</given-names></string-name>, <string-name><surname>Garfield</surname><given-names>JBB</given-names></string-name>, <string-name><surname>Clark</surname><given-names>SG</given-names></string-name>, <string-name><surname>Andrabi</surname><given-names>MN</given-names></string-name>, <string-name><surname>Lubman</surname><given-names>DI</given-names></string-name>. <article-title>A personalized approach bias modification smartphone app (‘SWiPE’) to reduce alcohol use: open‐label feasibility, acceptability, and preliminary effectiveness study</article-title>. <source>J Med Internet Res Mhealth Uhealth</source>. <year>2021</year>;<volume>9</volume>:<elocation-id>e31353</elocation-id>.</mixed-citation>
              </ref>
              <ref id="add15989-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0023"><string-name><surname>Napper</surname><given-names>LE</given-names></string-name>, <string-name><surname>Fisher</surname><given-names>DG</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>ME</given-names></string-name>, <string-name><surname>Wood</surname><given-names>MM</given-names></string-name>. <article-title>The reliability and validity of drug users’ self reports of amphetamine use among primarily heroin and cocaine users</article-title>. <source>Addict Behav</source>. <year>2010</year>;<volume>35</volume>:<fpage>350</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">20053503</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0024"><string-name><surname>Simons</surname><given-names>JS</given-names></string-name>, <string-name><surname>Wills</surname><given-names>TA</given-names></string-name>, <string-name><surname>Emery</surname><given-names>NN</given-names></string-name>, <string-name><surname>Marks</surname><given-names>RM</given-names></string-name>. <article-title>Quantifying alcohol consumption: self‐report, transdermal assessment, and prediction of dependence symptoms</article-title>. <source>Addict Behav</source>. <year>2015</year>;<volume>50</volume>:<fpage>205</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">26160523</pub-id></mixed-citation>
              </ref>
              <ref id="add15989-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="add15989-cit-0025"><string-name><surname>Manning</surname><given-names>V</given-names></string-name>, <string-name><surname>Garfield</surname><given-names>JB</given-names></string-name>, <string-name><surname>Best</surname><given-names>D</given-names></string-name>, <string-name><surname>Berends</surname><given-names>L</given-names></string-name>, <string-name><surname>Room</surname><given-names>R</given-names></string-name>, <string-name><surname>Mugavin</surname><given-names>J</given-names></string-name>, et al. <article-title>Substance use outcomes following treatment: findings from the Australian patient pathways study</article-title>. <source>Aust NZ J Psychiatry</source>. <year>2017</year>;<volume>51</volume>:<fpage>177</fpage>–<lpage>89</lpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
